Horizon applies expertise for iPSC cell line engineering services

The development of therapeutic treatments is a challenging process linked to understanding mechanisms that underly human disorders. Finding the relevant biological model has been a limiting process so far. The development of induced pluripotent stem cell (iPSC) technology has revolutionised the way we study complex disorders. iPSCs offer a unique in vitro platform for generating large quantities of cells for disease modelling, drug screening, and ultimately cell-based therapy. By combining such a platform with CRISPR-Cas9 gene editing technology, Horizon says it is able to unlock the potential to produce engineered iPSCs for a range of tissues and diseases.

Leveraging more than a decade of cell line engineering experience and with its optimal workflows, Horizon says it is able to deploy a highly efficient and highly scalable iPSC gene-editing platform to offer a range of cell line engineering services ranging from: gene knockout; single nucleotide polymorphism (SNP) or point mutations; fluorescent reporter cell lines and inducible gene expression.

In its poster the company explains its gene editing platform and capabilities to edit complex pluripotent stem cells for disease modelling.

Download the poster here.


Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free